Hikma Pharmaceuticals PLC Annual Report 2014 NOTES TO THE COMPANY FINANCIAL STATEMENTS continued 58.
NET INCOME FOR THE YEAR As permitted by section 408 of the Companies Act 2006, the statement of comprehensive income of the Company is not presented as partofthese accounts.
The net income in the Company for the year is $361 million 2013: $35 million.
Included in the net income for the year is an amount of $398 million 2013: $56 million representing dividends received and $2 million 2013:$1 million representing the current-year charge of LTIPs.
The remaining $6 million 2013: $6 million of the Groups stock options, LTIPsandMIPs charge is recharged to subsidiary companies.
RELATED PARTIES Darhold Limited: is a related party of the Company because it is considered one of the major shareholders of Hikma Pharmaceuticals PLC with ownership percentage of 28.8% at the end of 2014 2013: 28.9%.
Further details on the relationship between Mr Samih Darwazah, Mr Said Darwazah, Mr Mazen Darwazah and Mr Ali Al-Husry, and Darhold Limited are given in the Directors Report.
Arab Bank: is a related party of the Company because one Hikma Pharmaceuticals PLC senior management member is also a board member of Arab Bank PLC.
Total cash balances at Arab Bank were $48 million 31 December 2013: $5 million.
Facilities granted by Arab Bank to the Company amounted to $37 million 31 December 2013: $92 million.
Interest expense income is within the market rate.
Amounts repayable to and from subsidiaries are disclosed in Notes 45 and 49.
Other transactions with related parties include management charges for services provided to the subsidiary companies, equity-settled employee share scheme costs relating to the subsidiary companies and transactions with key management personnel.
Compensation paid to key management personnel is disclosed in Note 38.
Details of Directors remuneration are disclosed in the Remuneration Committee Report on pages 90 to 109.
More details on the general information of the ultimate parent of the Group are disclosed in Note 2.
